Bridge Biotherapeutics: 30% or more change in sales or profit/loss (15% or more for large companies)
30% or more change in sales or profit/loss (15% or more for larger companies)
|1. Type of financial statements||Consolidated financial statements|
|2. Details of changes in sales or profit/loss (KRW)||Current fiscal year||Previous exercice||Amount increased/decreased||Rate of increase/decrease (%)|
|– Sales (Limited to the amount of revenue based on sales of goods and services provided)||1,924,158,150||6,339,946,467||-4,415,788,317||-70.00|
|– Operating result||-26,391,767,980||-19,578,220,215||-6,813,547,765||-35.00|
|– Earnings from continuing operations before corporation tax||-26 278 291 392||-19,232,492,177||-7,045,799,215||-37.00|
|– Net revenue||-26 278 291 392||-19,232,492,177||-7,045,799,215||-37.00|
|– Applicability of large-scale society||No|
|3. Financial situation (KRW)||Current fiscal year||Previous exercice|
|– Total assets||46,657,249,917||63 510 099 312|
|– Total responsibilities||3,609,930,975||4,282,024,005|
|– Total equity||43,047,318,942||59 228 075 307|
|– share capital||9,853,712,500||9,590,587,000|
|4. Main reasons for changes in sales or profit/loss||
1. Reasons for changes in sales.
Fluctuation in profits due to the company’s business model
2. Reasons for profit and loss change.
Increase in stock-based compensation costs.
|5. Board resolution date (decision date)||2022-03-07|
|– Presence of external directors||Present (No.)||3|
|– Presence of the Statutory Auditors (members of the Audit Committee)||–|
|6. Other references regarding investment decisions||
1. Consolidated financial statements for the current year (2021) are based on K-IFRS
2. The consolidated financial statements for the previous year (2020) are based on the consolidated audit report for the same year.
3. The above content is subject to change after the external audit and the Annual General Meeting of Shareholders.
|※ Relevant disclosure||–|
|Note that this disclosure includes unaudited information and some details may change based on audit results.|
Bridge Biotherapeutics Inc. published this content on March 08, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on March 08, 2022 01:00:08 UTC.
Public now 2022
Evolution of the income statement